Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Viktor Grünwald, MD, PhD, on patterns of progression and subsequent therapy for patients with advanced RCC treated during the phase 3 CLEAR trial.

Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC

Aaron Gerds, MD, discusses updated efficacy and safety results for pelabresib and ruxolitinib in JAK inhibitor–naive myelofibrosis.


Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis

Treatment with asciminib led to a superior 48-week major molecular response rate vs investigator-selected TKIs in patients with Ph-positive chronic phase chronic myeloid leukemia.

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

Lorlatinib extended PFS and improved time to intracranial progression vs crizotinib in patients with ALK-positive non–small cell lung cancer.

Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Here is your guide to important regulatory approvals made by the FDA in May 2024.

OncLive’s May Roundup of Key FDA Approvals in Oncology

A new study may open life-saving opportunities for Hispanic patients, who are one-third less likely to find a fully matched donor from the national registry than white patients.

Half-Matched Family Donors Offer Best Outcomes for Hispanic Patients Undergoing Bone Marrow Transplants

Ivonescimab monotherapy improved PFS vs pembrolizumab in the first-line treatment of PD-L1–positive NSCLC in China.

First-Line Ivonescimab Improves PFS vs Pembrolizumab in PD-L1+ NSCLC in China

The FDA accepted the resubmission of the BLA for first-line zolbetuximab in CLDN18.2-positive, HER2-negative, advanced gastric or GEJ adenocarcinoma. 

FDA Accepts BLA Resubmission for Zolbetuximab in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Post-Conference Perspectives: Managing R/R B-ALL with CAR T-Cell Therapy

Videos

Jae Park, MD, reviews key data in the management of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) recently presented at the ASCO 2023 Annual Meeting.

Jae Park, MD, explains how B-cell acute lymphoblastic leukemia is diagnosed, and the testing done for detection of genetic abnormalities, which impacts treatment and prognosis.

Signs and Symptoms of B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Dr Jae Park details the treatment options for relapsed/refractory B-cell acute lymphoblastic leukemia, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, with the treatment choice dependent on patient factors like comorbidities, disease burden, and transplant status.

Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL

Jae Park, MD, reviews updated data from the ZUMA-3 trial on the use of the CAR T-cell therapy brexucabtagene autoleucel (brexu-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia, noting high remission rates, management of side effects like cytokine release syndrome, and post-CAR-T consolidation, including transplant.

R/R B-ALL: Key Efficacy Outcomes From the Updated Analysis of the ZUMA-3 Trial

Dr Jae Park discusses managing cytokine release syndrome and the neurotoxicity side effects of CAR T-cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia through medications, disease burden reduction, and earlier intervention to prevent severe toxicities.

R/R B-ALL: Key Safety Outcomes From the Updated Analysis of the ZUMA-3 Trial

Jae Park, MD, explains how real-world CAR T-cell therapy data in patients with relapsed/refractory B-cell acute lymphoblastic leukemia shows high response rates but emphasizes the ongoing need for optimizing toxicity management, with trends toward earlier treatment and cell collection.

Outcomes Data Following Brexucabtagene Autoleucel Therapy in Patients With R/R B-ALL

Dr Jae Park shares his experience with using brexucabtagene autoleucel for patients with relapsed/refractory B-cell acute lymphoblastic leukemia in clinical practice since its FDA approval in October 2021.

An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice

Jae Park, MD, wraps up his discussion by highlighting exciting investigational agents on the horizon for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

The Future of R/R B-ALL Treatment

An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice

EP: 1.Signs and Symptoms of B-Cell Acute Lymphoblastic Leukemia (B-ALL)

EP: 2.Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL

EP: 3.R/R B-ALL: Key Efficacy Outcomes From the Updated Analysis of the ZUMA-3 Trial

EP: 4.R/R B-ALL: Key Safety Outcomes From the Updated Analysis of the ZUMA-3 Trial

EP: 5.Outcomes Data Following Brexucabtagene Autoleucel Therapy in Patients With R/R B-ALL

EP: 6.An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice

EP: 7.The Future of R/R B-ALL Treatment

Latest Conference Coverage